Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03128723 · ClinicalTrials.gov registry record · NA
A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris
A NA study of Acne Vulgaris, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT03128723: Completed NA study of Acne Vulgaris, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).
NCT03128723 is a NA study of Acne Vulgaris that has completed, run by Johnson & Johnson Consumer Inc. (J&JCI). The registered enrollment target is 45 participants, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03128723, a NA study of Acne Vulgaris, has completed, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will look to evaluate the tolerance of a light therapy-based acne mask device in participants who report having sensitive skin. All participants will receive a cleanser, a light therapy mask, and an extra activator for the light therapy mask.
Primary Outcome
Cutaneous Tolerance Scores: Erythema (assessing skin redness), from Baseline to Day 28. Scale range is 0-3 where 0 = no redness, 1 = mild redness, 2 = moderate redness, and 3 = severe redness.
Conditions Studied
Interventions
- DEVICE Acne Mask
Study Locations (1)
Tennessee
- Tennessee Clinical Research Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2017-04-30 |
| Est. Completion | 2017-06-08 |
| Phase | NA |
What the finished NCT03128723 record still lists
NCT03128723 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which Acne Mask is the first listed.
NCT03128723 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT03128723 about?
NCT03128723 is a clinical study titled "A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris". The study will look to evaluate the tolerance of a light therapy-based acne mask device in participants who report having sensitive skin. All participants will receive a cleanser, a light therapy mask, and an extra activator for the light therapy mask.
What is the current status of trial NCT03128723?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2017-04-30. Estimated completion is 2017-06-08.
What conditions does trial NCT03128723 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT03128723?
The interventions under investigation include: Acne Mask (DEVICE).
Who is sponsoring clinical trial NCT03128723?
This trial is sponsored by Johnson & Johnson Consumer Inc. (J&JCI), which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03128723 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03128723's enrollment target sits among peer trials
45 49th of 67 higher than 19 of 67 other Acne Vulgaris trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Laser Treatment of Moderate to Severe Acne Vulgaris
ACTIVE NOT RECRUITING · NA
-
A Post Market Device Study for the Treatment of Acne
ACTIVE NOT RECRUITING · NA
-
A Clinical In-Use Evaluation to Assess the Tolerability and Efficacy of a Moisturizer on Acne Prone Skin
COMPLETED · NA
-
Comparison Between Interactive Internet-based Education and Counseling for the Management of Acne With That of Internet-based Education Alone
COMPLETED · NA
-
Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris
COMPLETED · NA
-
U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI